1. Home
  2. NGNE vs BTGO Comparison

NGNE vs BTGO Comparison

Compare NGNE & BTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$35.99

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo BitGo Holdings Inc. Class A Common Stock

BTGO

BitGo Holdings Inc. Class A Common Stock

N/A

Current Price

$5.55

Market Cap

692.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
BTGO
Founded
2003
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
692.3M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
NGNE
BTGO
Price
$35.99
$5.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
9
Target Price
$63.57
$14.83
AVG Volume (30 Days)
174.1K
1.1M
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$34.41
P/E Ratio
N/A
$10.81
Revenue Growth
N/A
N/A
52 Week Low
$15.93
$4.65
52 Week High
$43.66
$15.30

Technical Indicators

Market Signals
Indicator
NGNE
BTGO
Relative Strength Index (RSI) 53.66 57.92
Support Level $31.83 $5.42
Resistance Level $43.66 $5.72
Average True Range (ATR) 2.07 0.32
MACD 0.05 0.08
Stochastic Oscillator 72.75 99.46

Price Performance

Historical Comparison
NGNE
BTGO

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About BTGO BitGo Holdings Inc. Class A Common Stock

BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.

Share on Social Networks: